Glenview Capital's Q3 13F filing reveals increased stakes in Meta and Teva, reductions in CVS and Block, and full exits from Dick's Sporting Goods and STM.
Seeking Alpha
2 stories shown
Glenview Capital's Q3 13F filing reveals increased stakes in Meta and Teva, reductions in CVS and Block, and full exits from Dick's Sporting Goods and STM.
An analysis by CVS Health's Aetna indicates that GLP-1 medications priced below $350 monthly could generate net savings for payors.